New insulin could cut need for daily injections
By Stephen Robinson, 27 September 2010
A new insulin in development may remove the need for daily injections and reduce glucose fluctuations, research suggests.
Data from a phase-2 trial showed treatment with new insulin degludec led to a more stable glucose-lowering effect in patients with type-1 diabetes than standard treatment.
An accompanying study showed that insulin degludec injected three times a week was as effective at lowering HbA1c levels as existing type-2 diabetes therapy.
The data were presented at the European Association for the Study of Diabetes (EASD) meeting in Stockholm last week.
In the first study, 54 patients with type-1 diabetes were given either insulin degludec or insulin glargine once daily and monitored for 12 days. Researchers studied treatment effects for 24 hours at days 6, 9 and 12.
Researchers found that the variability of treatment effects was lower among patients given insulin degludec than standard treatment.
Findings from another study also suggested the new insulin could be administered less often, which could improve adherence to treatment in insulin-naïve patients.
In a phase-2 trial, three-times-weekly insulin degludec was shown to be as effective as a once daily dose of standard treatment.
A trial of 184 type-2 patients compared insulin degludec once daily or three-times-weekly with insulin glargine.
It showed that the three treatments produced similar reductions in HbA1c and number of adverse effects.
Dr Iain Frame, director of research at Diabetes UK, described the study as ‘a small step forward’ in producing a new insulin formulation.
‘The next stage will be to test the formulations on larger numbers of people for a longer time period,’ he said.
- Related Drug Categories
- Related MIMS Tables
- Finger Prickers and Compatible Lancets
- Insulin Preparations
- Blood Glucose Testing Strips and Meters
- Related MIMS Guidelines and Summaries
- Dapagliflozin in Combination Therapy for Treating Type 2 Diabetes (TA288)
- Exenatide Prolonged-Release Suspension for Injection in Combination with Oral Antidiabetic Therapy for the Treatment of Type 2 Diabetes (TA248)
- Liraglutide for the Treatment of Type 2 Diabetes Mellitus (TA203)
Latest Articles from GP
Latest jobs Jobs web feed
- Salaried GP / Partner The Lakeside Practice Negotiable, Doncaster
- GP & Lead GP Care UK Competitive + Benefits, Pentonville Prison- London
- General Practitioner - Westcliff-on-Sea, Essex CRG Locums £70.00 - £75.00, Westcliff-on-Sea
- GP Partner, Merthyr Tydfil 1403-422 Prospect Health £120000 per annum + 7 weeks holiday + NHS pension, Merthyr Tydfil
- Salaried GP, Milton Keynes 1402-1508 Prospect Health £85000 per annum + MDU fees paid + NHS pension, Milton Keynes
- Salaried GP, Bradford 1403-1084 Prospect Health £80000 per annum + MDU fees paid + 6 weeks holiday , Bradford